|Description||Cancer, Infectious Disease Treatment|
|Seed, 10/2007 ||$2.3M|
|Grant, 10/2007 |
The Texas Emerging Technology Fund
|Series A, 11/2009 ||$4.5M|
|Venture Round, 3/2011 ||$5.7M|
|Series B, 3/2012 |
Bellicum Pharmaceuticals, Inc. is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum’s novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. Our lead product, BP-GMAX-CD1, is in Phase I clinical trials.